Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Jackson

Showing results (151-160 of 182) with videos related to

Pageof 19
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|January 9, 2023
A Randomized Trial of a Composite T2-Biomarker Strategy Adjusting Corticosteroid Treatment in Severe Asthma: A Post Hoc Analysis by SexMatthew C Eastwood, John Busby, David J Jackson, et al.
Chest|December 1, 2019
Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma RegistryEileen Wang, Michael E Wechsler, Trung N Tran, et al.
The Lancet. Respiratory Medicine|March 24, 2023
Use of digital measurement of medication adherence and lung function to guide the management of uncontrolled asthma (INCA Sun): a multicentre, single-blinded, randomised clinical trialElaine Mac Hale, Garrett Greene, Christopher Mulvey, et al.
ERJ Open Research|February 10, 2021
The impact of the first COVID-19 surge on severe asthma patients in the UK. Which is worse: the virus or the lockdown?Steven J Smith, John Busby, Liam G Heaney, et al.
Pragmatic and Observational Research|August 19, 2021
Risk Predictors and Symptom Features of Long COVID Within a Broad Primary Care Patient Population Including Both Tested and Untested PatientsRupert Jones, Andrew Davis, Brooklyn Stanley, et al.
The Lancet. Respiratory Medicine|April 11, 2025
Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trialsFleur L Meulmeester, Samuel Mailhot-Larouche, Carlos Celis-Preciado, et al.
The Journal of Allergy and Clinical Immunology|June 14, 2023
Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma controlXue Zeng, Jing Qing, Chi-Ming Li, et al.
The Lancet. Respiratory Medicine|May 29, 2026
Asthma exacerbation profile of benralizumab for severe eosinophilic asthma (the BenRex study): a multicentre, prospective cohort studyJennifer Logan, Kirsty Martin, Lynsey Gillespie, et al.
American Journal of Respiratory and Critical Care Medicine|October 29, 2014
IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivoDavid J Jackson, Heidi Makrinioti, Batika M J Rana, et al.
American Journal of Respiratory and Critical Care Medicine|April 18, 2024
Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA StudyRatko Djukanović, Paul Brinkman, Johan Kolmert, et al.
Pageof 19

Showing results (151-160 of 182) with videos related to

Sort By:
Pageof 19
The Journal of Allergy and Clinical Immunology. in Practice|January 9, 2023
A Randomized Trial of a Composite T2-Biomarker Strategy Adjusting Corticosteroid Treatment in Severe Asthma: A Post Hoc Analysis by SexMatthew C Eastwood, John Busby, David J Jackson, et al.
Chest|December 1, 2019
Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma RegistryEileen Wang, Michael E Wechsler, Trung N Tran, et al.
The Lancet. Respiratory Medicine|March 24, 2023
Use of digital measurement of medication adherence and lung function to guide the management of uncontrolled asthma (INCA Sun): a multicentre, single-blinded, randomised clinical trialElaine Mac Hale, Garrett Greene, Christopher Mulvey, et al.
ERJ Open Research|February 10, 2021
The impact of the first COVID-19 surge on severe asthma patients in the UK. Which is worse: the virus or the lockdown?Steven J Smith, John Busby, Liam G Heaney, et al.
Pragmatic and Observational Research|August 19, 2021
Risk Predictors and Symptom Features of Long COVID Within a Broad Primary Care Patient Population Including Both Tested and Untested PatientsRupert Jones, Andrew Davis, Brooklyn Stanley, et al.
The Lancet. Respiratory Medicine|April 11, 2025
Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trialsFleur L Meulmeester, Samuel Mailhot-Larouche, Carlos Celis-Preciado, et al.
The Journal of Allergy and Clinical Immunology|June 14, 2023
Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma controlXue Zeng, Jing Qing, Chi-Ming Li, et al.
The Lancet. Respiratory Medicine|May 29, 2026
Asthma exacerbation profile of benralizumab for severe eosinophilic asthma (the BenRex study): a multicentre, prospective cohort studyJennifer Logan, Kirsty Martin, Lynsey Gillespie, et al.
American Journal of Respiratory and Critical Care Medicine|October 29, 2014
IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivoDavid J Jackson, Heidi Makrinioti, Batika M J Rana, et al.
American Journal of Respiratory and Critical Care Medicine|April 18, 2024
Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA StudyRatko Djukanović, Paul Brinkman, Johan Kolmert, et al.
Pageof 19